
IGMS Stock Forecast & Price Target
IGMS Analyst Ratings
Bulls say
IGM Biosciences Inc. is positioned favorably within the biotechnology sector, supported by its innovative IgM antibody technology platform, which has the potential to revolutionize treatments for various diseases. The company's collaboration with SNY for developing novel IgM agonists suggests a promising pipeline with nearly $3 billion in potential milestone revenues, reflecting significant financial upside if the candidates prove successful. Furthermore, the differentiated cytokine profile and acceptable safety associated with IgM-based antagonists bolster a positive outlook and could enhance the company's market competitiveness in the rapidly evolving therapeutic landscape.
Bears say
IGM Biosciences Inc. faces significant downside risk primarily due to its inability to advance key internal programs or secure external assets, leading to a potential fair value of $0.50, which is below the cash per share value. The recent decision to discontinue its primary value-driving bispecific T-cell engager clinical pipeline, alongside a substantial workforce reduction, highlights operational challenges and raises concerns about the company's future viability. Compounding these issues are the disappointing efficacy results of its drug candidates, Aplitabart and Imvotamab, and the discontinuation of IGM-2644, further reinforcing a negative outlook amidst ongoing financial instability and high volatility.
This aggregate rating is based on analysts' research of IGM Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
IGMS Analyst Forecast & Price Prediction
Start investing in IGMS
Order type
Buy in
Order amount
Est. shares
0 shares